Health & Fitness
Tue, December 27, 2011Mon, December 26, 2011Fri, December 23, 2011Thu, December 22, 2011Wed, December 21, 2011Tue, December 20, 2011Mon, December 19, 2011Sun, December 18, 2011Sat, December 17, 2011Fri, December 16, 2011Thu, December 15, 2011Wed, December 14, 2011Savient Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
//health-fitness.news-articles.net/content/2011/ .. 0th-annual-j-p-morgan-healthcare-conference.html
Published in Health and Fitness on Tuesday, December 20th 2011 at 13:12 GMT by Market WireSavient Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare... -- EAST BRUNSWICK, N.J., Dec. 20, 2011 /PRNewswire/ --
Savient Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
EAST BRUNSWICK, N.J., Dec. 20, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: [ SVNT ]) today announced that John H. Johnson, Chief Executive Officer and President of Savient will present at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012 at 10:30 AM Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.
A live webcast of the presentation can be accessed through the investor relations section of the Company's website at [ www.savient.com ]. Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at [ www.savient.com ].
SVNT - G
Contact: |
|
Mary Coleman | Carney Noensie |
Savient Pharmaceuticals, Inc. | Burns McClellan |
(732) 418-9300 | (212) 213-0006 |
SOURCE Savient Pharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.savient.com ]
